RxDoctor Payments DataLook up a doctor →

Lucky Flores, MD

Adult Medicine · Miami Lakes, FLNPI 1225007669

Payments from drug & device makers

$4,242,518in general payments, 2019–2025

Across 933 payments — averaging $4547.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$874K
  • Eli Lilly$803K
  • AbbVie$631K
  • Takeda Pharmaceuticals U.S.A., Inc.$588K
  • Genentech, Inc.$487K
  • AstraZeneca$279K
  • plus $581K from 13 others
$16,861in research payments, 2019–2025

Across 30 payments — averaging $562.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$13K
  • Sanofi US Services Inc.$3K
  • AbbVie$537

What the payments were for

  • Consulting fees$1,58351%
  • Travel & lodging$65621%
  • Food & beverage$84027%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,242,518 in reported general payments places this provider in the 95th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$21,052
Medicare patients
40
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate13$20,689
EliquisApixaban13$17,838
TrulicityDulaglutide12$11,597
LinzessLinaclotide19$11,165
Ventolin HfaAlbuterol Sulfate61$3,432
Tadalafil14$3,374
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$3,273
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,661
Pen NeedlesPen Needle, Diabetic31$2,120
Esomeprazole Magnesium18$1,502
Albuterol Sulfate HfaAlbuterol Sulfate36$1,259
Clobetasol Propionate11$877
LantusInsulin Glargine,hum.Rec.Anlog11$760
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide15$743
Atorvastatin Calcium178$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$94$20,68913 claims
PfizerEliquis$873,986$17,83813 claims
AbbVieLinzess$630,564$11,16519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Miami Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →